Webinar: Reliable Results, Rapid Delivery: Performance Evaluation of Oncomine Comprehensive Assay Plus and the Ion Torrent Genexus System

Webinar summary

This webinar presents an integrated health system’s evaluation of the Oncomine Comprehensive Assay Plus on the Ion GeneStudio S5 System for solid tumor research on over 6,000 pan-cancer samples.

Despite more than half of the samples coming from challenging cytology specimens with no pre-testing exclusion, the assay achieved a 97.2% reporting success rate across a range of tumor types.

Particularly noteworthy was the observation that the small number of failures in both pancreatobiliary and lung samples were predominantly limited to samples with very low DNA input (<0.5–1 ng), demonstrating robust performance even in low cellularity cytology samples that would likely have been excluded from testing using alternative approaches.

Following the strong performance of the assay on the GeneStudio S5 System, Dr. Campbell evaluated the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to assess workflow efficiency and concordance. The Genexus System reduced total run time from 72 hours with the GeneStudio workflow to 32 hours, a reduction of more than 50%. Its highly automated workflow also reduced technician hands-on time from 15 hours to just 2 hours, representing a reduction of more than 85%.

Overall, implementing the Oncomine Comprehensive Assay Plus on the Genexus System significantly improved turnaround time and reduced hands-on time, while maintaining high concordance with testing performed on the GeneStudio System.

Key findings

• High success with challenging samples: Geisinger achieved a 97.2% CGP success rate with the Oncomine Comprehensive Assay Plus on the GeneStudio S5 System across >6,000 research samples, despite 55.4% being cytology samples.
  
  
• Automation drives workflow efficiency: Oncomine Comprehensive Assay Plus on the Genexus System reduced the workflow to approximately 2 hours of technician time, compared with 15 hours on the GeneStudio S5 workflow, while improving turnaround time.
  
  
• Performance is maintained with automation: Initial Oncomine Comprehensive Assay Plus results on the Genexus System showed high concordance with the GeneStudio S5 System, supporting the potential to gain speed and efficiency without sacrificing analytical consistency in the evaluated research samples.

Conclusion

Dr. Campbell's experience demonstrated a 97% sequencing success rate with the manual Oncomine Comprehensive Assay Plus workflow on GeneStudio, including successful sequencing with DNA inputs as low as 0.5 ng.

In preliminary testing, Oncomine Comprehensive Assay Plus on Genexus reduced turnaround time and technologist hands-on time while showing high concordance with GeneStudio results. Future evaluation will assess whether similarly high success rates can be achieved with low-input samples on Genexus.